Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

ABSTRACT: The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

DISEASE(S): Breast Carcinoma,Carcinoma,Anal Carcinoma,Biliary Tract Neoplasms,Cervical Carcinoma,Mesothelioma,Liver Cancer,Testicular Cancer,Endometrial Neoplasms,Breast Neoplasms,Pancreatic Carcinoma,Soft Tissue Sarcomas,Esophageal Neoplasms,Renal,Gastric Cancer,Pancreatic Neoplasms,Carcinoma Of Unknown Origin, Primary,Bone Sarcomas,Colorectal,Sarcoma,Melanoma,Small Cell Lung Carcinoma,Ovarian,Gallbladder Cancer,Esophageal Carcinoma,Carcinoma, Neuroendocrine,Biliary Tract Cancer,Thyroid Cancer,Neuroendocrine Cancer,Gallbladder Neoplasms,Prostate,Testicular Neoplasms,Endometrial Carcinoma

PROVIDER: 2036215 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR